Synthesis, characterization, molecular docking, analgesic, antiplatelet and anticoagulant effects of dibenzylidene ketone derivatives

Table 4 Inhibitory effect of (2E,5E)-2-(4-methoxybenzylidene)-5-(4-nitrobenzylidene) cyclopentanone (AK-1a) and (1E,4E)-4-(4-nitrobenzylidene)-1-(4-nitrophenyl)oct-1-en-3-one (AK-2a) and aspirin against arachidonic acid (AA) and adenosine diphosphate (ADP)-induced platelet aggregation

Treatment	Agonist	Inhibition of platelet aggregation (%) ± SEM							IC₅₀ (µM)
Treatment	Agonist	1 µM	3 µM	10 µM	30 µM	100 µM	300 µM	1000 µM	IC₅₀ (µM)
AK-1a	AA	2.3 ± 0.06	7.2 ± 0.06	20.4 ± 0.06	33.2 ± 0.14	55.6 ± 0.20	67.1 ± 0.15	88.5 ± 0.18	65.2
AK-1a	ADP	1.81 ± 0.04	4.4 ± 0.04	13.4 ± 0.06	22.4 ± 0.04	31 ± 0.06	42.6 ± 0.06	54.1 ± 0.06	750.4
AK-2a	AA	4.3 ± 0.07	10.5 ± 0.09	28 ± 0.15	42.7 ± 0.22	62.2 ± 0.08	78.9 ± 0.19	89.8 ± 0.13	37.7
AK-2a	ADP	4.4 ± 0.04	4.4 ± 0.07	14.2 ± 0.02	18.6 ± 0.06	30.2 ± 0.07	48.3 ± 0.12	56.8 ± 0.06	422
Aspirin	AA	27.2 ± 0.18	36 ± 0.09	50.1 ± 0.16	59.7 ± 0.09	100 ± 0	100 ± 0	100 ± 0	10.01
Aspirin	ADP	3.6 ± 0.07	6.2 ± 0.09	19.1 ± 0.07	25 ± 0.06	32.8 ± 0.10	49.8 ± 0.12	56.9 ± 0.18	308.4

ISSN: 2661-801X